CLLS Cellectis
Price (delayed)
$2.36
Market cap
$236.22M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.25
Enterprise value
$197.36M
cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene
Highlights
CLLS's equity has surged by 64% since the previous quarter and by 54% year-on-year
CLLS's gross margin is up by 2.6% year-on-year
The company's gross profit has surged by 64% QoQ but it fell by 19% YoY
The revenue has soared by 62% from the previous quarter but it is down by 21% YoY
CLLS's quick ratio is down by 26% year-on-year and by 14% since the previous quarter
Key stats
What are the main financial stats of CLLS
Market
Valuations
Earnings
Shares outstanding
100.09M
Market cap
$236.22M
Enterprise value
$197.36M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.14
Price to sales (P/S)
10.81
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.05
Revenue
$19.64M
EBIT
-$49.75M
EBITDA
-$30.8M
Free cash flow
$49.64M
Per share
Balance sheet
Liquidity
EPS
-$1.25
Free cash flow per share
$0.55
Book value per share
$2.07
Revenue per share
$0.22
TBVPS
$4.52
Total assets
$407.15M
Total liabilities
$258.54M
Debt
$110.19M
Equity
$148.61M
Working capital
$146.17M
Debt to equity
0.74
Current ratio
1.92
Quick ratio
1.86
Net debt/EBITDA
1.26
Margins
Efficiency
Dividend
EBITDA margin
-156.9%
Gross margin
98.2%
Net margin
-407.3%
Operating margin
-450%
Return on assets
-24.5%
Return on equity
-80%
Return on invested capital
-30.5%
Return on capital employed
-20.1%
Return on sales
-253.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CLLS stock price
How has the Cellectis stock price performed over time
Intraday
0.85%
1 week
2.16%
1 month
13.46%
1 year
44.79%
YTD
-23.38%
QTD
26.2%
Financial performance
How have Cellectis's revenue and profit performed over time
Revenue
$19.64M
Gross profit
$19.29M
Operating income
-$88.36M
Net income
-$79.97M
Gross margin
98.2%
Net margin
-407.3%
The company's gross profit has surged by 64% QoQ but it fell by 19% YoY
The revenue has soared by 62% from the previous quarter but it is down by 21% YoY
Cellectis's operating margin has increased by 42% from the previous quarter but it has decreased by 39% YoY
The company's net margin rose by 26% QoQ but it fell by 3.9% YoY
Growth
What is Cellectis's growth rate over time
Valuation
What is Cellectis stock price valuation
P/E
N/A
P/B
1.14
P/S
10.81
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.05
The company's EPS rose by 37% YoY but it fell by 11% QoQ
CLLS's equity has surged by 64% since the previous quarter and by 54% year-on-year
The P/B is 34% less than the 5-year quarterly average of 1.7 and 19% less than the last 4 quarters average of 1.4
The revenue has soared by 62% from the previous quarter but it is down by 21% YoY
The price to sales (P/S) is 29% lower than the 5-year quarterly average of 15.0 and 8% lower than the last 4 quarters average of 11.7
Efficiency
How efficient is Cellectis business performance
CLLS's return on invested capital has dropped by 77% since the previous quarter and by 5% year-on-year
CLLS's ROA is up by 36% year-on-year but it is down by 3.8% since the previous quarter
The company's return on sales fell by 11% QoQ and by 3.7% YoY
The return on equity has declined by 4.8% since the previous quarter but it has grown by 4.2% year-on-year
Dividends
What is CLLS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CLLS.
Financial health
How did Cellectis financials performed over time
CLLS's total assets is 57% greater than its total liabilities
Cellectis's total liabilities has soared by 97% YoY but it has decreased by 2% from the previous quarter
CLLS's total assets has surged by 79% year-on-year and by 15% since the previous quarter
The company's debt is 26% lower than its equity
CLLS's equity has surged by 64% since the previous quarter and by 54% year-on-year
CLLS's debt to equity is down by 43% since the previous quarter and by 28% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.